走进利拉鲁肽 更多 >>
继日本中央社会保险医疗委员会批准了Victoza®（利拉鲁肽）的定价之后，诺和诺德制药公司计划将尽快在当地市场推出这种产品。诺和诺德表示，Victoza®是首个在日本获准上市的GLP-1类药物，既可以单独用药，也可以作为辅助药物与磺脲类降糖药(SU)联用。
Defining and characterising the progression of type 2 diabetes
β细胞的持续性凋亡是2型糖尿病的重要特征，并且不因为多种治疗方法而逆转；其次，胰岛α细胞功能的损害其实也在糖尿病的进程中起到重要作用。
Type 2 diabetes is a progressive disease characterised by worsening of multiple abnormalities and loss of glycaemic control over time. An increasing need for glucose-lowering treatments is emphasised by the almost inevitable failure of monotherapy and occurrence of weight gain. Longer survival times and development of type 2 diabetes at a younger age also increase the risk of developing microvascular and macrovascular complications.
A hallmark of type 2 diabetes mellitus is declining pancreatic β-cell function, which begins years before diagnosis and continues throughout the disease process.This deterioration continues despite initiation of numerous therapies, as these interventions lower glucose but do not directly slow β-cell decline and dysfunction. Defects in α-cell function are also important contributors to disease progression. New therapies that can counter these abnormalities without causing weight gain or hypoglycaemia continue to be assessed.
编辑: helen
以下网友留言只代表网友个人观点，不代表网站观点
